Updates on Chemotherapy-Induced Nausea and Vomiting Management

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric patients with cerebellar tumors.

Sarah Sammons;Rachel A. Freedman;Adam M. Brufsky;Ahmad Awada;Sara A. Hurvitz, MD;Nancy U. Lin, MD;Cristina Saura;Sheri Leung;Bethann S Hromatka

PROSTOX Ultra Reliably Predicts Long-Term Radiation AEs in Prostate Cancer

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

Roman Fabbricatore

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Caroline Welsh;Nicole Taylor;Julie Cole;Manjeet Chadha

Durvalumab Combo Shows Encouraging Preliminary Data in High-Risk UTUC

Russ Conroy

Auditory Attention Decay Noted Post-Treatment in Pediatric Cerebellar Tumors

Combining durvalumab with chemotherapy produced a good safety profile without increasing surgical risk in the phase 2 iNDUCT-GETUG V08 trial.

Related Content

Ariana Pelosci

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric patients with cerebellar tumors.

Sarah Sammons;Rachel A. Freedman;Adam M. Brufsky;Ahmad Awada;Sara A. Hurvitz, MD;Nancy U. Lin, MD;Cristina Saura;Sheri Leung;Bethann S Hromatka

PROSTOX Ultra Reliably Predicts Long-Term Radiation AEs in Prostate Cancer

Roman Fabbricatore

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Caroline Welsh;Nicole Taylor;Julie Cole;Manjeet Chadha

Durvalumab Combo Shows Encouraging Preliminary Data in High-Risk UTUC

Russ Conroy